International Clinical Trial: JCOG2403: A randomized phase III trial of adjuvant therapy with BRAF/MEK inhibitors versus anti-PD-1 antibody in resected stage IIB/IIC and microscopic stage III BRAF V600-mutant melanoma

Geneva, Sept. 23 -- International Clinical Trials Registry received information related to the study (JPRN-jRCT1031250352) titled 'JCOG2403: A randomized phase III trial of adjuvant therapy with BRAF/MEK inhibitors versus anti-PD-1 antibody in resected stage IIB/IIC and microscopic stage III BRAF V600-mutant melanoma' on Sept. 10.

Study Type: Interventional

Study Design: randomized controlled trial, open(masking not used), active control, parallel assignment, treatment purpose

Primary Sponsor: Namikawa Kenjiro

Condition: Stage IIB/IIC and microscopic stage III BRAF V600-mutant melanoma

Intervention: Arm A: Adjuvant systemic therapy with pembrolizumab (200 mg every 3 weeks or 400 mg every 6 weeks), or nivolumab (240 mg every 2 week...